GE Healthcare and MDS Pharma Services this week announced the availability of a new micronucleus assay protocol for GE Healthcare's IN Cell 1000 and 3000 high-content screening platforms that is expected to more accurately predict genotoxicity in early-stage drug discovery.

The assay will be available as part of MDS Pharma's contract pharmaceutical research offerings and is a key component of its growing portfolio of early-stage, cell-based assays for assessing the potential toxicity of drug candidates.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.